Oncolytics Biotech (ONCY) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Oncolytics Biotech (ONCY) over the past year, gaining 2.0% versus a loss of 57.5%. Over five years, ONCY leads with a -75.5% price change compared with -91.7% for PDSB. PDS Biotechnology is the larger company by market cap ($73.9 million vs $71.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONCY | PDSB |
|---|---|---|
| Share price | $0.5444 | $1.02 |
| Market cap | $71.38M | $73.92M |
| 1-day change | -8.63% | -4.23% |
| YTD return | -37.43% | +32.47% |
| 1-year return | -57.47% | +2.00% |
| 5-year return | -75.48% | -91.73% |
| EPS (TTM) | $-0.35 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.32 | $1.55 |
| 52-week low | $0.54 | $0.195 |
| Distance from 52-week high | -58.76% | -34.19% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +662.31% | +390.20% |
| Average volume | 1.08M | 23.18M |
| Shares outstanding | 131.12M | 72.47M |
| Employees | 29 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed ONCY by 59.5 percentage points over the past year.
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Healthcare · Biotechnology · 29 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Healthcare · Biotechnology · 21 employees
ONCY vs PDSB FAQ
Which is bigger, Oncolytics Biotech or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $73.92M compared with $71.38M for Oncolytics Biotech (ONCY).
Which stock has performed better over the past year, ONCY or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Oncolytics Biotech and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.